{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:34:19Z","timestamp":1781948059946,"version":"3.54.5"},"reference-count":395,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,8]],"date-time":"2027-01-08T00:00:00Z","timestamp":1799366400000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019284","name":"UH Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtho.2025.11.002","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:17:29Z","timestamp":1767863849000},"page":"41-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-8474","authenticated-orcid":false,"given":"Michele","family":"Carbone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Amos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Attanoos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Boeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian R.","family":"Chirieac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Galateau-Salle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Giannakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra V.","family":"Goparaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Minaai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsetsuya","family":"Mitsudomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry J.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Montuenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nabeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Passaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Samet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Schrump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Sozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Taioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia D.","family":"Vison\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.11.002_bib3","first-page":"365","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","author":"Aberle","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial","volume":"382","author":"de Koning","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtho.2025.11.002_bib6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib7","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1016\/S0140-6736(24)01299-6","article-title":"Lung cancer treatment: 20 years of progress","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib10","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib11","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib12","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib13","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMoa2212083","article-title":"Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer","volume":"388","author":"Altorki","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.chest.2025.04.022","article-title":"A prospective, multicenter evaluation of safety and diagnostic outcomes with robotic-assisted bronchoscopy: results of the transbronchial biopsy assisted by robot guidance in the evaluation of tumors of the lung (TARGET) trial","volume":"168","author":"Murgu","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2025.11.002_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11701-025-02727-1","article-title":"National adoption of robotic-assisted thoracoscopic surgery for oncologic lung resections","volume":"19","author":"Reddington","year":"2025","journal-title":"J Robot Surg"},{"key":"10.1016\/j.jtho.2025.11.002_bib17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2018.1258","article-title":"Long-term results of stereotactic body radiation therapy in medically inoperable Stage I non-small cell lung cancer","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"National Lung Screening Trial Research Team","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib19","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for lung cancer: US Preventive Services Task Force Recommendation Statement","volume":"325","author":"US Preventive Services Task Force","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2025.11.002_bib20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.athoracsur.2005.07.078","article-title":"Video-assisted thoracic surgery lobectomy: experience with 1,100 cases","volume":"81","author":"McKenna","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2025.11.002_bib21","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","article-title":"Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802\/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial","volume":"399","author":"Saji","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jtcvs.2016.04.085","article-title":"Robotic lobectomy can be taught while maintaining quality patient outcomes","volume":"152","author":"Cerfolio","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.11.002_bib23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2025.11.002_bib24","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib25","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib26","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.ijrobp.2025.06.1179","article-title":"Ten-year outcomes of the revised STARS trial comparing radiation and surgery for early-stage non-small cell lung cancer","volume":"123","author":"Kleber","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2025.11.002_bib27","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib30","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib31","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib32","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline","volume":"7","author":"Videtic","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib34","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Zer","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jtho.2023.03.013","article-title":"Did the ban on asbestos reduce the incidence of mesothelioma?","volume":"18","author":"Carbone","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib36","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jtho.2023.01.095","article-title":"Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study","volume":"18","author":"Huang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/oemed-2022-108669","article-title":"Incidence and mortality from malignant mesothelioma 1982-2020 and relationship with asbestos exposure: the Australian mesothelioma Registry","volume":"80","author":"Walker-Bone","year":"2023","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib38","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2025.11.002_bib39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/PAT.0b013e3283631cce","article-title":"Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy","volume":"45","author":"Lee","year":"2013","journal-title":"Pathology"},{"key":"10.1016\/j.jtho.2025.11.002_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PAS.0000000000001545","article-title":"Malignant mesothelioma of the peritoneum in women: a clinicopathologic study of 164 cases","volume":"45","author":"Malpica","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib41","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jtho.2025.06.020","article-title":"Clinical and pathologic phenotyping of mesotheliomas developing in carriers of germline BAP1 mutations","volume":"20","author":"Carbone","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib42","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin cisplatin pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib43","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jtho.2024.01.017","article-title":"Immunotherapy is a good standard option for patients with malignant pleural mesothelioma, despite the real-world results from Australia","volume":"19","author":"Smesseim","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib44","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2024.01.016","article-title":"Based on the real-world results from Australia, immunotherapy is not a good option for patients with mesothelioma","volume":"19","author":"Gray","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2007.10.054","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.11.002_bib46","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib47","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jtho.2024.12.014","article-title":"A perspective on the MARS2 trial","volume":"20","author":"Lim","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib49","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(00)04013-7","article-title":"Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey","volume":"357","author":"Roushdy-Hammady","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib50","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib51","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2025.11.002_bib54","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib55","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib56","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib57","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/his.12779","article-title":"Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK-related tumour spectrum","volume":"68","author":"Loharamtaweethong","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2025.11.002_bib59","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.11.002_bib60","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111946118","article-title":"BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene \u00d7 environment interaction with asbestos","volume":"118","author":"Novelli","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib61","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib62","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2405231121","article-title":"Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling","volume":"121","author":"Novelli","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib63","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.jtho.2025.07.132","article-title":"Prospective analysis of mesotheliomas in subjects with BAP1 cancer syndrome: clinical characteristics and epigenetic correlates of disease","volume":"20","author":"Wu","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227197","article-title":"Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States","volume":"14","author":"Hsu","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2025.11.002_bib65","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11604-023-01497-w","article-title":"Review of clinical and diagnostic imaging of the thymus: from age-related changes to thymic tumors and everything in between","volume":"42","author":"Yamada","year":"2024","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.jtho.2025.11.002_bib66","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jtho.2022.02.001","article-title":"Trends in incidence and survival of patients with thymic epithelial tumor in a high-incidence Asian country: analysis of the Korean central cancer registry 1999 to 2017","volume":"17","author":"Shin","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib67","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (remora): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib68","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37508","article-title":"Association of stage shift and population mortality among patients with non-small cell lung cancer","volume":"4","author":"Flores","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtho.2025.11.002_bib69","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib70","doi-asserted-by":"crossref","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jtho.2025.11.002_bib71","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1513\/AnnalsATS.202209-802OC","article-title":"Global, regional, and national burden of mesothelioma 1990\u20132019: a systematic analysis of the global burden of disease Study 2019","volume":"20","author":"Han","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jtho.2025.11.002_bib72","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2022.01.021","article-title":"Thymic carcinomas-A concise multidisciplinary update on recent developments from the thymic carcinoma working group of the international thymic malignancy interest group","volume":"17","author":"Roden","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib73","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer","volume":"354","author":"Alexandrov","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jtho.2025.11.002_bib74","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S1470-2045(13)70487-X","article-title":"The carcinogenicity of outdoor air pollution","volume":"14","author":"Loomis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41586-025-09219-0","article-title":"The mutagenic forces shaping the genomes of lung cancer in never smokers","volume":"644","author":"D\u00edaz-Gay","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.11.002_bib76","doi-asserted-by":"crossref","DOI":"10.1289\/EHP10669","article-title":"Lung cancer and radon: pooled analysis of uranium Miners Hired in 1960 or later","volume":"130","author":"Richardson","year":"2022","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jtho.2025.11.002_bib77","unstructured":"Institute for Health Metrics and Evaluation. GBD results. https:\/\/vizhub.healthdata.org\/gbd-results\/. Accessed December 4, 2025."},{"key":"10.1016\/j.jtho.2025.11.002_bib78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.lungcan.2020.08.012","article-title":"Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis","volume":"148","author":"Ang","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib79","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/jnci\/82.15.1272","article-title":"Evidence for Mendelian inheritance in the pathogenesis of lung cancer","volume":"82","author":"Sellers","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2025.11.002_bib80","first-page":"157","article-title":"Evidence for a major gene effect in early-onset lung cancer","volume":"145","author":"Bailey-Wilson","year":"1993","journal-title":"J La State Med Soc"},{"key":"10.1016\/j.jtho.2025.11.002_bib81","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ajmg.1320520311","article-title":"Segregation analysis of smoking-associated malignancies: evidence for Mendelian inheritance","volume":"52","author":"Sellers","year":"1994","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib82","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/(SICI)1098-2272(199911)17:4<253::AID-GEPI2>3.0.CO;2-K","article-title":"Lung cancer risk in families of nonsmoking probands: heterogeneity by age at diagnosis","volume":"17","author":"Yang","year":"1999","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.jtho.2025.11.002_bib83","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1086\/423857","article-title":"A major lung cancer susceptibility locus maps to chromosome 6q23-25","volume":"75","author":"Bailey-Wilson","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib84","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1158\/0008-5472.CAN-09-3096","article-title":"A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers","volume":"70","author":"Amos","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib85","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00439-003-0968-7","article-title":"Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk","volume":"113","author":"Hwang","year":"2003","journal-title":"Hum Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib86","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/jnci\/92.24.2037","article-title":"Hereditary retinoblastoma and risk of lung cancer","volume":"92","author":"Kleinerman","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2025.11.002_bib87","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/ng1671","article-title":"Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR","volume":"37","author":"Bell","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib88","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/JTO.0000000000000130","article-title":"Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations","volume":"9","author":"Gazdar","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib89","doi-asserted-by":"crossref","first-page":"498","DOI":"10.21037\/tlcr.2018.06.01","article-title":"Inherited lung cancer syndromes targeting never smokers","volume":"7","author":"Yamamoto","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib90","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/cas.13233","article-title":"Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer","volume":"108","author":"Tode","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2025.11.002_bib91","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/jhg.2015.75","article-title":"Germline mutations causing familial lung cancer","volume":"60","author":"Tomoshige","year":"2015","journal-title":"J Hum Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib92","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01809-2023","article-title":"High risk of lung cancer in surfactant-related gene variant carriers","volume":"63","author":"Brudon","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2025.11.002_bib93","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1093\/hmg\/ddad095","article-title":"Candidate pathway analysis of surfactant proteins identifies CTSH and SFTA2 that influences lung cancer risk","volume":"32","author":"Luyapan","year":"2023","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib94","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ajhg.2008.11.010","article-title":"Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer","volume":"84","author":"Wang","year":"2009","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib95","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ajhg.2014.12.016","article-title":"A recurrent mutation in PARK2 is associated with familial lung cancer","volume":"96","author":"Xiong","year":"2015","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib96","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2217\/fon.15.79","article-title":"PARK2 gene and familial lung cancer: what is the link?","volume":"11","author":"Xiong","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib97","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/s41467-020-15905-6","article-title":"Protein-altering germline mutations implicate novel genes related to lung cancer development","volume":"11","author":"Ji","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.11.002_bib98","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ijc.34510","article-title":"A rare FGF5 candidate variant (rs112475347) for predisposition to nonsquamous, nonsmall-cell lung cancer","volume":"153","author":"Cannon-Albright","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010902","article-title":"Large-scale whole exome sequencing studies identify two genes,CTSL and APOE, associated with lung cancer","volume":"19","author":"Xu","year":"2023","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib100","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/cpt.1971","article-title":"Genetic variant in CHRNA5 and response to varenicline and combination nicotine replacement in a randomized placebo-controlled trial","volume":"108","author":"Chen","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtho.2025.11.002_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.addicn.2023.100083","article-title":"Genomic medicine to reduce tobacco and related disorders: translation to precision prevention and treatment","volume":"7","author":"Chen","year":"2023","journal-title":"Addict Neurosci"},{"key":"10.1016\/j.jtho.2025.11.002_bib102","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv100","article-title":"CHRNA5 risk variant predicts delayed Smoking Cessation and earlier lung cancer diagnosis--a meta-analysis","volume":"107","author":"Chen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2025.11.002_bib103","unstructured":"Chen T., Pham G, Fox L, et al. Genomic insights for personalized care: motivating at-risk individuals toward evidence-based health practices. https:\/\/www.medrxiv.org\/content\/10.1101\/2024.03.19.24304556v5.full. Accessed December 4, 2025."},{"key":"10.1016\/j.jtho.2025.11.002_bib104","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/ntr\/ntac268","article-title":"Influence of CYP2A6 genetic variation, nicotine dependence severity, and treatment on smoking cessation success","volume":"25","author":"Chenoweth","year":"2023","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib105","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/ijc.32771","article-title":"Transcriptome-wide association study reveals candidate causal genes for lung cancer","volume":"146","author":"Boss\u00e9","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib106","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ajhg.2009.09.012","article-title":"A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma","volume":"85","author":"Landi","year":"2009","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib107","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11684-020-0779-4","article-title":"Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma","volume":"15","author":"Qin","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib108","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/carcin\/bgv165","article-title":"Fine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci","volume":"37","author":"Kachuri","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2025.11.002_bib109","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1158\/1055-9965.EPI-18-1215","article-title":"Investigation of leukocyte telomere length and genetic variants in chromosome 5p15.33 as prognostic markers in lung cancer","volume":"28","author":"Kachuri","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtho.2025.11.002_bib110","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/ng.3892","article-title":"Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes","volume":"49","author":"McKay","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib111","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1038\/s41467-018-05890-2","article-title":"Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity","volume":"9","author":"Ferreiro-Iglesias","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.11.002_bib112","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21062-1","article-title":"KIR-HLA gene diversities and susceptibility to lung cancer","volume":"12","author":"Hematian Larki","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2025.11.002_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi3808","article-title":"An immunogenetic basis for lung cancer risk","volume":"383","author":"Krishna","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jtho.2025.11.002_bib114","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/jnci\/djq232","article-title":"Nicotinic acetylcholine receptor region on Chromosome 15q25 and lung cancer risk among African Americans: a case-control study","volume":"102","author":"Amos","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2025.11.002_bib115","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/ng.109","article-title":"Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1","volume":"40","author":"Amos","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib116","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1055-9965.EPI-20-1635","article-title":"The shared genetic architectures between lung cancer and multiple polygenic phenotypes in genome-wide association studies","volume":"30","author":"Byun","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtho.2025.11.002_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105441","article-title":"Genomic insights for personalised care in lung cancer and smoking cessation: motivating at-risk individuals toward evidence-based health practices","volume":"110","author":"Chen","year":"2024","journal-title":"EBiomedicine"},{"key":"10.1016\/j.jtho.2025.11.002_bib118","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jtho.2019.04.008","article-title":"Lung cancer risk in never-smokers of European descent is associated with genetic variation in the 5p15.33 TERT-CLPTM1Ll region","volume":"14","author":"Hung","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib119","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/1055-9965.EPI-16-0106","article-title":"The OncoArray consortium: a network for understanding the genetic architecture of common cancers","volume":"26","author":"Amos","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtho.2025.11.002_bib120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-069X-6-7","article-title":"Lung cancers attributable to environmental tobacco smoke and air pollution in non-smokers in different European countries: a prospective study","volume":"6","author":"Vineis","year":"2007","journal-title":"Environ Health"},{"key":"10.1016\/j.jtho.2025.11.002_bib121","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jpeds.2008.06.039","article-title":"Newborn sickle cell screening in a region of Western New York State","volume":"154","author":"Lerner","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.jtho.2025.11.002_bib122","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/archinte.1958.00260140209031","article-title":"Differences between smokers and nonsmokers","volume":"101","author":"HEATH","year":"1958","journal-title":"AMA Arch Intern Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib123","author":"Hamilton"},{"key":"10.1016\/j.jtho.2025.11.002_bib124","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ajhg.2015.06.009","article-title":"The genetic basis of Mendelian phenotypes: discoveries, challenges, and opportunities","volume":"97","author":"Chong","year":"2015","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/RTI.0000000000000136","article-title":"Computed tomography screening for lung cancer in the national lung screening trial: a cost-effectiveness analysis","volume":"30","author":"Black","year":"2015","journal-title":"J Thorac Imaging"},{"key":"10.1016\/j.jtho.2025.11.002_bib126","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","volume":"17","author":"Villani","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib127","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1158\/0008-5472.CAN-20-1237","article-title":"Assessing lung cancer absolute risk trajectory based on a polygenic risk model","volume":"81","author":"Hung","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib128","unstructured":"US Preventive Services Task Force. Final recommendation statement. Lung cancer: screening. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/lung-cancer-screening. Accessed December 4, 2025."},{"key":"10.1016\/j.jtho.2025.11.002_bib129","unstructured":"Centers for Medicare & Medicaid Services. National coverage determination (NCD): lung cancer screening with low dose computed tomography (LDCT). https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncd.aspx?ncdid=364&ncdver=1. Accessed December 4, 2025."},{"key":"10.1016\/j.jtho.2025.11.002_bib130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.rcl.2024.12.007","article-title":"Lung-RADS v2022 update","volume":"63","author":"Agrawal","year":"2025","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.jtho.2025.11.002_bib132","unstructured":"Centers for Medicare & Medicaid Services. National coverage determination (NCD) 210.14 reconsideration \u2013 screening for lung cancer with low dose computed tomography (LDCT). https:\/\/www.cms.gov\/files\/document\/mm12691-national-coverage-determination-ncd-21014-reconsideration-screening-lung-cancer-low-dose.pdf. Accessed December 4, 2025."},{"key":"10.1016\/j.jtho.2025.11.002_bib133","first-page":"50","article-title":"Screening for lung cancer: 2023 guideline update from the American Cancer Society","volume":"74","author":"Wolf","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2025.11.002_bib134","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jamainternmed.2024.1655","article-title":"Lung cancer screening in the US, 2022","volume":"184","author":"Bandi","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/260170a0","article-title":"DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA","volume":"260","author":"Stehelin","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.11.002_bib136","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","article-title":"Oncogene addiction","volume":"68","author":"Weinstein","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib137","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jtho.2025.11.002_bib138","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib139","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jtho.2025.11.002_bib140","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1056\/NEJMra1504688","article-title":"Clinical implications of genomic discoveries in lung cancer","volume":"374","author":"Swanton","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib141","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2025.11.002_bib142","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.002_bib143","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-09-0913","article-title":"Integration of molecular profiling into the lung cancer clinic","volume":"15","author":"Pao","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib144","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/JTO.0000000000000516","article-title":"Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience","volume":"10","author":"Sholl","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib145","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/1078-0432.CCR-17-2289","article-title":"The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the lung cancer mutation consortium (LCMC2)","volume":"24","author":"Aisner","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib146","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/cncr.29042","article-title":"Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium","volume":"121","author":"Villaruz","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib147","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/cncr.30869","article-title":"HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium","volume":"123","author":"Pillai","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib148","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/cncr.29812","article-title":"Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: results from the Lung Cancer Mutation Consortium","volume":"122","author":"Steuer","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib149","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jtho.2019.01.020","article-title":"Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer mutation consortium experience","volume":"14","author":"El Osta","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib150","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib151","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib152","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib153","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib154","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib155","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib156","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib157","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib158","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib159","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-013-0170-8","article-title":"Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jtho.2025.11.002_bib161","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib162","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib163","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib164","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib165","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in Stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib166","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib167","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib168","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 Phase III trial","volume":"39","author":"Zhong","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib169","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","article-title":"Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial","volume":"6","author":"Yue","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib170","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.22.00428","article-title":"Updated overall survival and exploratory analysis from randomized, Phase II EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage IIIA epidermal growth factor receptor+ non-small-cell lung cancer","volume":"40","author":"Yue","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib171","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41392-022-01286-3","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial","volume":"8","author":"Zhong","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtho.2025.11.002_bib172","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer","volume":"43","author":"He","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib173","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib174","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib175","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib176","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jtho.2024.01.012","article-title":"Consolidation Osimertinib versus Durvalumab versus observation after concurrent chemoradiation in unresectable EGFR-mutant NSCLC: a multicenter retrospective cohort study","volume":"19","author":"Nassar","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib177","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ijrobp.2014.05.135","article-title":"Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable Stage I non-small cell lung cancer","volume":"90","author":"Timmerman","year":"2014","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib178","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib179","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamaoncol.2024.1841","article-title":"Long-term prospective outcomes of intensity modulated radiotherapy for locally advanced lung cancer: a secondary analysis of a randomized clinical trial","volume":"10","author":"Chun","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib181","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","article-title":"Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial","volume":"21","author":"Nestle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib182","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib183","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib184","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (Caspian): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib185","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib186","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib187","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib188","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib189","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib190","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib191","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib192","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib193","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib194","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib195","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib196","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib197","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib198","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib199","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib200","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib201","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib202","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib203","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.23.00258","article-title":"Early-stage lung cancer: using circulating tumor DNA to get personal","volume":"41","author":"Bestvina","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib204","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006284","article-title":"Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA","volume":"11","author":"Semenkovich","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib205","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib206","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies","volume":"40","author":"Passaro","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib207","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib208","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-024-00985-w","article-title":"Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?","volume":"22","author":"Normanno","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib209","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1158\/1078-0432.CCR-05-2324","article-title":"Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer","volume":"12","author":"Kimura","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib210","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-14-2594","article-title":"Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy","volume":"21","author":"Mok","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib211","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib212","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2025.11.002_bib213","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41571-020-0423-x","article-title":"Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice","volume":"18","author":"Aggarwal","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib214","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib215","article-title":"Liquid biopsy of lung cancer before pathological diagnosis is associated with shorter time to treatment","volume":"8","author":"Russo","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib216","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.11.002_bib217","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.002_bib218","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib219","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.annonc.2023.12.010","article-title":"Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer","volume":"35","author":"Rolfo","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100272","article-title":"Liquid biopsy through non-blood fluids: the show must go on","volume":"6","author":"Dipasquale","year":"2024","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.jtho.2025.11.002_bib221","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jtho.2018.11.023","article-title":"Biomarkers in lung cancer screening: achievements, promises, and challenges","volume":"14","author":"Seijo","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib222","doi-asserted-by":"crossref","first-page":"e614","DOI":"10.1016\/S2589-7500(24)00123-7","article-title":"Evaluation of risk prediction models to select lung cancer screening participants in Europe: a prospective cohort consortium analysis","volume":"6","author":"Feng","year":"2024","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.jtho.2025.11.002_bib223","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJMoa1214726","article-title":"Probability of cancer in pulmonary nodules detected on first screening CT","volume":"369","author":"McWilliams","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib224","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.lungcan.2008.07.012","article-title":"Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer","volume":"64","author":"Paci","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1164\/rccm.200807-1068OC","article-title":"Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study","volume":"179","author":"Sozzi","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib226","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04367-2020","article-title":"Biomarkers in lung cancer screening: the importance of study design","volume":"57","author":"Baldwin","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2025.11.002_bib227","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1055-9965.EPI-22-0689","article-title":"Development of a molecular blood-based immune signature classifier as biomarker for risks assessment in lung cancer screening","volume":"31","author":"Fortunato","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtho.2025.11.002_bib228","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jtho.2016.08.143","article-title":"Autoantibody signature enhances the positive predictive power of computed tomography and nodule-based risk models for detection of lung cancer","volume":"12","author":"Massion","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib229","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1073\/pnas.1100048108","article-title":"MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer","volume":"108","author":"Boeri","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib230","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/jnci\/djad122","article-title":"Circulating proteome for pulmonary nodule malignancy","volume":"115","author":"Khodayari Moez","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2025.11.002_bib231","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1038\/s41467-023-37979-8","article-title":"The blood proteome of imminent lung cancer diagnosis","volume":"14","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.11.002_bib232","article-title":"Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging","volume":"57","author":"Sullivan","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2025.11.002_bib233","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.annonc.2022.01.008","article-title":"Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial","volume":"33","author":"Pastorino","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib234","article-title":"Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial","volume":"46","author":"Boeri","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jtho.2025.11.002_bib235","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.2078","article-title":"Assessment of lung cancer risk on the basis of a biomarker panel of circulating proteins","volume":"4","author":"Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib236","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.annepidem.2022.10.014","article-title":"Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program","volume":"77","author":"Robbins","year":"2023","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.jtho.2025.11.002_bib237","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(23)00277-2","article-title":"Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study","volume":"24","author":"Nicholson","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib238","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","article-title":"Detection and characterization of lung cancer using cell-free DNA fragmentomes","volume":"12","author":"Mathios","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.11.002_bib239","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib240","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/2159-8290.CD-24-0519","article-title":"Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection","volume":"14","author":"Mazzone","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.002_bib241","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jtho.2025.01.021","article-title":"New horizons in lung cancer screening: eligibility criteria, risk models, and emerging challenges","volume":"20","author":"Boeri","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib242","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jtho.2020.06.001","article-title":"A grading system for invasive pulmonary adenocarcinoma: a proposal from the International Association for the Study of Lung Cancer pathology committee","volume":"15","author":"Moreira","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib243","first-page":"S589","article-title":"The 2011 IASLC\/ATS\/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management","volume":"6","author":"Tang","year":"2014","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtho.2025.11.002_bib244","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib245","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00292-014-1974-3","article-title":"The 2015 WHO classification of lung tumors","volume":"35","author":"Travis","year":"2014","journal-title":"Pathologe"},{"key":"10.1016\/j.jtho.2025.11.002_bib246","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib247","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib248","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41571-025-01011-3","article-title":"Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials","volume":"22","author":"Ernst","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib249","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib250","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib251","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.ccell.2022.10.022","article-title":"Evaluation of cell-free DNA approaches for multi-cancer early detection","volume":"40","author":"Jamshidi","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2025.11.002_bib252","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jtho.2023.04.022","article-title":"Immune infiltration in tumor and adjacent non-neoplastic regions Codetermines patient clinical outcomes in early-stage lung cancer","volume":"18","author":"Cheng","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib253","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1378\/chest.08-0978","article-title":"The new lung cancer staging system","volume":"136","author":"Detterbeck","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2025.11.002_bib254","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib255","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/JTO.0b013e3181a0d82e","article-title":"The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer","volume":"4","author":"Rusch","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib256","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib257","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.chest.2024.05.026","article-title":"The proposed ninth edition TNM classification of lung cancer","volume":"166","author":"Detterbeck","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2025.11.002_bib258","doi-asserted-by":"crossref","first-page":"e211S","DOI":"10.1378\/chest.12-2355","article-title":"Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Silvestri","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2025.11.002_bib259","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/ejcts\/ezu028","article-title":"Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer","volume":"45","author":"De Leyn","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2025.11.002_bib260","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.chest.2024.08.056","article-title":"Acquisition and handling of endobronchial ultrasound transbronchial needle samples: an American College of Chest Physicians clinical practice guideline","volume":"167","author":"Gilbert","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2025.11.002_bib261","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jtcvs.2010.11.008","article-title":"Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial","volume":"141","author":"Darling","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.11.002_bib262","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jtho.2022.03.015","article-title":"Reclassifying the International Association for the Study of Lung Cancer residual tumor classification according to the extent of nodal dissection for NSCLC: one size does not fit all","volume":"17","author":"Lee","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib263","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.athoracsur.2020.05.144","article-title":"Survival after thoracoscopic surgery or open lobectomy: systematic review and meta-analysis","volume":"111","author":"Hernandez-Vaquero","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2025.11.002_bib264","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.athoracsur.2012.10.070","article-title":"Uniportal video-assisted thoracoscopic lobectomy: two years of experience","volume":"95","author":"Gonzalez-Rivas","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2025.11.002_bib265","first-page":"1489","article-title":"Uniportal VATS-a new era in lung cancer surgery","volume":"7","author":"Ng","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtho.2025.11.002_bib266","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11701-025-02852-x","article-title":"Robotic-assisted vs video-assisted thoracoscopic lobectomy for non-small cell lung cancer: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials on surgical quality, perioperative, and oncologic outcomes","volume":"19","author":"Mirza","year":"2025","journal-title":"J Robot Surg"},{"key":"10.1016\/j.jtho.2025.11.002_bib267","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.21037\/tcr-21-646","article-title":"Robotic and video-assisted lobectomy\/segmentectomy for non-small cell lung cancer have similar perioperative outcomes: a systematic review and meta-analysis","volume":"10","author":"Mao","year":"2021","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib268","first-page":"S6","article-title":"PLO3.13 survival outcome of VATS compared to open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials","volume":"20","author":"Law","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib269","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jtcvs.2023.07.008","article-title":"Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance)","volume":"167","author":"Altorki","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.11.002_bib270","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1007\/s00464-016-5329-4","article-title":"Indocyanine green fluorescence-navigated robotic segmentectomy","volume":"31","author":"Hsieh","year":"2017","journal-title":"Surg Endosc"},{"key":"10.1016\/j.jtho.2025.11.002_bib271","article-title":"AI-based chest CT semantic segmentation algorithm enables semi-automated lung cancer surgery planning by recognizing anatomical variants of pulmonary vessels","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib272","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib273","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in Stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib274","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO-24-01681","article-title":"Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non-small cell lung cancer (IMpower010): an open-label, randomized, Phase III trial","volume":"43","author":"Felip","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib275","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib276","article-title":"Burden of laryngeal cancer attributable to occupational asbestos exposure in China: a comprehensive analysis from 1990 to 2021","volume":"20","author":"Chen","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2025.11.002_bib277","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00432-024-05802-6","article-title":"Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990\u20132019","volume":"150","author":"Chen","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib278","doi-asserted-by":"crossref","DOI":"10.1136\/bmjph-2024-001717","article-title":"Global mortality burden of lung cancer and mesothelioma attributable to occupational asbestos exposure and the impact of national asbestos ban policies: a population-based study, 1990\u20132021","volume":"3","author":"Li","year":"2025","journal-title":"BMJ Public Health"},{"key":"10.1016\/j.jtho.2025.11.002_bib279","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0035-1549449","article-title":"Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues","volume":"36","author":"Markowitz","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib280","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/ijc.34881","article-title":"Occupational asbestos exposure and risk of esophageal cancer: a systematic review and meta-analysis","volume":"154","author":"Seyyedsalehi","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib281","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/JTO.0000000000000506","article-title":"The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from Southern Nevada","volume":"10","author":"Baumann","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib282","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1073\/pnas.1105887108","article-title":"Erionite exposure in North Dakota and Turkish villages with mesothelioma","volume":"108","author":"Carbone","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib283","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2068","article-title":"A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes","volume":"7","author":"Carbone","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib284","doi-asserted-by":"crossref","first-page":"239","DOI":"10.21037\/atm.2017.04.06","article-title":"The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad","volume":"5","author":"Emri","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib285","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib286","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1289\/ehp.1104287","article-title":"Mitochondria-derived reactive intermediate species mediate asbestos-induced genotoxicity and oxidative stress-responsive signaling pathways","volume":"120","author":"Huang","year":"2012","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jtho.2025.11.002_bib287","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101616","article-title":"Asbestos conceives Fe(II)-dependent mutagenic stromal milieu through ceaseless macrophage ferroptosis and beta-catenin induction in mesothelium","volume":"36","author":"Ito","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.jtho.2025.11.002_bib288","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib289","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1156995","article-title":"Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica","volume":"320","author":"Dostert","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jtho.2025.11.002_bib290","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1186\/s12967-023-04614-5","article-title":"Preventive and therapeutic opportunities: targeting BAP1 and\/or HMGB1 pathways to diminish the burden of mesothelioma","volume":"21","author":"Carbone","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib291","doi-asserted-by":"crossref","first-page":"25543","DOI":"10.1073\/pnas.2007622117","article-title":"Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy","volume":"117","author":"Xue","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib292","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1002\/jcp.30125","article-title":"HMGB1 as a therapeutic target in disease","volume":"236","author":"Xue","year":"2021","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jtho.2025.11.002_bib293","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.1073\/pnas.0604008103","article-title":"TNF-\u03b1 inhibits asbestos-induced cytotoxicity via a NF-\u03baB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis","volume":"103","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib294","first-page":"659","article-title":"High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE\/NF-\u03baB signaling pathway","volume":"53","author":"Zhang","year":"2018","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib295","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","article-title":"Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-alpha signaling","volume":"183","author":"Qi","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib296","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307999120","article-title":"HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma","volume":"120","author":"Suarez","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib297","doi-asserted-by":"crossref","first-page":"238","DOI":"10.21037\/atm.2017.04.29","article-title":"Mesothelioma: recent highlights","volume":"5","author":"Carbone","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib298","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.153","article-title":"Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression","volume":"6","author":"Yang","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jtho.2025.11.002_bib299","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/1476-4598-9-314","article-title":"Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin","volume":"9","author":"Shukla","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib300","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.jtho.2025.07.132","article-title":"Prospective analysis of mesotheliomas in subjects with BAP1 cancer syndrome: clinical characteristics and epigenetic correlates of disease","volume":"20","author":"Wu","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib301","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological mechanisms and clinical significance of BAP1 mutations in human cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.002_bib302","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib303","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib304","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib305","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1078-0432.CCR-23-2431","article-title":"Niraparib plus Dostarlimab in pleural mesothelioma or non-small cell lung cancer harboring HRR mutations: interim results of the UNITO-001 Phase II prospective trial","volume":"30","author":"Passiglia","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib306","doi-asserted-by":"crossref","first-page":"33466","DOI":"10.1073\/pnas.2019652117","article-title":"Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma","volume":"117","author":"Bononi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib307","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70990","article-title":"Estimating cancer penetrance in carriers of BRCA2 pathogenic variants using cancer-specific polygenic scores","volume":"14","author":"Prassas","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib308","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/cdd.2017.95","article-title":"Germline BAP1 mutations induce a Warburg effect","volume":"24","author":"Bononi","year":"2017","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jtho.2025.11.002_bib309","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217840120","article-title":"BAP1 is a novel regulator of HIF-1alpha","volume":"120","author":"Bononi","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.11.002_bib310","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41419-018-1206-5","article-title":"BAP1 regulates different mechanisms of cell death","volume":"9","author":"Affar","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jtho.2025.11.002_bib311","first-page":"OF1","article-title":"Co-targeting BCL-xL with MCL-1 induces lethal mitochondrial dysfunction in diffuse mesothelioma","author":"Xu","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2025.11.002_bib312","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/JTO.0000000000000466","article-title":"Recent insights emerging from malignant mesothelioma genome sequencing","volume":"10","author":"Carbone","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib313","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib314","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK rearrangements in malignant peritoneal mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib315","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103644","article-title":"Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms","volume":"9","author":"Benzerdjeb","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2025.11.002_bib316","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.5858\/arpa.2023-0213-RA","article-title":"Molecular and immunohistochemical testing in mesothelioma and other mesothelial lesions","volume":"148","author":"Hung","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib317","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib318","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib319","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: a potential test for malignant pleural mesothelioma","volume":"53","author":"Beyer","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.jtho.2025.11.002_bib320","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/0008-5472.CAN-09-3993","article-title":"hsa-miR-29c\u2217 is linked to the prognosis of malignant pleural mesothelioma","volume":"70","author":"Pass","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.002_bib321","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib322","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib323","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jtho.2021.05.018","article-title":"Serum proteomics and plasma Fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases","volume":"16","author":"Tsim","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib324","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32315-3","article-title":"Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers","volume":"8","author":"Johnen","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2025.11.002_bib325","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00408-019-00244-1","article-title":"Mesothelin, calretinin, and megakaryocyte potentiating factor as biomarkers of malignant pleural mesothelioma","volume":"197","author":"Jim\u00e9nez-Ram\u00edrez","year":"2019","journal-title":"Lung"},{"key":"10.1016\/j.jtho.2025.11.002_bib326","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-039079","article-title":"Re-evaluation of potential predictors of calretinin and mesothelin in a population-based cohort study using assays for the routine application in clinical medicine","volume":"11","author":"Casjens","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtho.2025.11.002_bib327","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107802","article-title":"Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients","volume":"192","author":"Klotz","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib328","series-title":"World Health Organization Classification of Tumours, Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart","first-page":"128","article-title":"Tumours of the pleura: mesothelial tumours","author":"Churg","year":"2004"},{"key":"10.1016\/j.jtho.2025.11.002_bib329","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5858\/arpa.2018-0457-OA","article-title":"Differential diagnosis of epithelioid malignant mesothelioma with lung and breast pleural metastasis: a systematic review compared with a standardized panel of antibodies-A new proposal that may influence pathologic practice","volume":"144","author":"Le Stang","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib330","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00000478-200404000-00013","article-title":"Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases","volume":"28","author":"Galateau-Sall\u00e9","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib331","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2025.11.002_bib332","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","article-title":"Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas","volume":"453","author":"Dacic","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2025.11.002_bib333","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/ijms19040988","article-title":"NF2\/merlin inactivation and potential therapeutic targets in mesothelioma","volume":"19","author":"Sato","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2025.11.002_bib334","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib335","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.5858\/arpa.2012-0112-RA","article-title":"The separation of benign and malignant mesothelial proliferations","volume":"136","author":"Churg","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib336","article-title":"Malignant mesothelioma of the pleura with pleomorphic features: a series of 44 cases","volume":"90","author":"Galateau-Salle","year":"2010","journal-title":"Lab Investig. 75 VARICK ST: NATURE PUBLISHING GROUP, 9TH FLR, NEW YORK, NY 10013-1917 USA"},{"key":"10.1016\/j.jtho.2025.11.002_bib337","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/JTO.0b013e318211127a","article-title":"Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma","volume":"6","author":"Kadota","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib338","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41379-021-00900-z","article-title":"Molecular characterization of pleomorphic mesothelioma: a multi-institutional study","volume":"35","author":"Roy","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib339","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/cam4.572","article-title":"The clinicopathological significance of NAB2-STAT6 gene fusions in 52 cases of intrathoracic solitary fibrous tumors","volume":"5","author":"Huang","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib340","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/PAS.0000000000000346","article-title":"Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions","volume":"39","author":"Anderson","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib341","first-page":"9","article-title":"Desmoid tumors of the pleura: a clinicopathologic mimic of localized fibrous tumor","volume":"12","author":"Wilson","year":"1999","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib342","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250619","article-title":"Clinicopathological features of 70 desmoid-type fibromatoses confirmed by beta-catenin immunohistochemical staining and CTNNB1 mutation analysis","volume":"16","author":"An","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2025.11.002_bib343","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.002_bib344","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBiomedicine"},{"key":"10.1016\/j.jtho.2025.11.002_bib345","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","article-title":"Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity","volume":"55","author":"Mangiante","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2025.11.002_bib346","article-title":"Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib347","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib348","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.5858\/arpa.2023-0304-RA","article-title":"Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the international mesothelioma interest group","volume":"148","author":"Husain","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib349","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","article-title":"Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations","volume":"17","author":"Carbone","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib350","series-title":"Thoracic Tumours","year":"2021"},{"key":"10.1016\/j.jtho.2025.11.002_bib351","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib352","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41379-022-01082-y","article-title":"Well differentiated papillary mesothelial tumor: a new name and new problems","volume":"35","author":"Churg","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib353","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/PAS.0000000000002033","article-title":"Mesothelioma in situ mimicking well-differentiated papillary mesothelial tumor","volume":"47","author":"Galateau-Salle","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib354","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41379-018-0127-2","article-title":"Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42","volume":"32","author":"Stevers","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib355","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41379-019-0347-0","article-title":"Malignant mesothelioma in situ: morphologic features and clinical outcome","volume":"33","author":"Churg","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib356","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2018.07.041","article-title":"Highlights of the 14th international mesothelioma interest group meeting: pathologic separation of benign from malignant mesothelial proliferations and histologic\/molecular analysis of malignant mesothelioma subtypes","volume":"124","author":"Churg","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib357","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2020.09.002","article-title":"Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ","volume":"149","author":"Dacic","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib358","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41379-021-00895-7","article-title":"Pleural mesothelioma classification-update and challenges","volume":"35","author":"Dacic","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib359","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s00428-005-0035-y","article-title":"Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases","volume":"447","author":"Shia","year":"2005","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2025.11.002_bib360","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2020.01.025","article-title":"Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH reference center","volume":"15","author":"Galateau Salle","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib361","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41379-019-0320-y","article-title":"Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas","volume":"33","author":"Dacic","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib362","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41379-021-00899-3","article-title":"Solid papillary mesothelial tumor","volume":"35","author":"Churg","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib363","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib364","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib365","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41379-022-01081-z","article-title":"Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma","volume":"35","author":"Chapel","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib366","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib367","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamaoncol.2023.6789","article-title":"Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: the ATOMIC-Meso randomized clinical trial","volume":"10","author":"Szlosarek","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib368","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.002_bib369","article-title":"A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern","volume":"3","author":"Kerrigan","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2025.11.002_bib370","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib371","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.002_bib372","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtho.2025.11.002_bib373","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.002_bib374","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib375","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtho.2025.11.002_bib376","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(24)00191-8","volume":"25","author":"Aerts","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib377","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1443910","article-title":"The thymus road to a T cell: migration, selection, and atrophy","volume":"15","author":"Ruiz P\u00e9rez","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2025.11.002_bib378","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00281-021-00842-3","article-title":"Thymus and autoimmunity","volume":"43","author":"Marx","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jtho.2025.11.002_bib379","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib380","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2025.11.002_bib381","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jtho.2021.02.008","article-title":"A tuft cell-like signature is highly prevalent in thymic squamous cell carcinoma and delineates new molecular subsets among the major lung cancer histotypes","volume":"16","author":"Yamada","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib382","article-title":"Abnormal cellular populations shape thymic epithelial tumor heterogeneity and anti-tumor by blocking metabolic interactions in organoids","volume":"11","author":"Liu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jtho.2025.11.002_bib383","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1038\/s41467-022-33170-7","article-title":"The immune landscape of human thymic epithelial tumors","volume":"13","author":"Xin","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.11.002_bib384","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114677","article-title":"Spatial transcriptomics elucidates medulla niche supporting germinal center response in myasthenia gravis-associated thymoma","volume":"43","author":"Yasumizu","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2025.11.002_bib385","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-07944-6","article-title":"A spatial human thymus cell atlas mapped to a continuous tissue axis","volume":"635","author":"Yayon","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.11.002_bib386","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s11912-025-01680-4","article-title":"Therapeutic management of metastatic thymoma and thymic carcinoma","volume":"27","author":"Girard","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jtho.2025.11.002_bib387","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3390\/cancers16071369","article-title":"Immunotherapy for thymomas and thymic carcinomas: current status and future directions","volume":"16","author":"Rajan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2025.11.002_bib388","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/cncr.34678","article-title":"Understanding the landscape of immunotherapy in thymic epithelial tumors","volume":"129","author":"Maniar","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib389","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtho.2025.11.002_bib390","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5597","article-title":"Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance","volume":"11","author":"Ferr\u00e9","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2025.11.002_bib391","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10875-024-01760-3","article-title":"Lymphocyte-directed immunomodulation remits thymoma-associated autoimmune pneumonitis","volume":"44","author":"Ferr\u00e9","year":"2024","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jtho.2025.11.002_bib392","series-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","author":"Travis","year":"2015"},{"key":"10.1016\/j.jtho.2025.11.002_bib393","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2559.2008.03088.x","article-title":"Interobserver variation in the classification of thymic tumours--a multicentre study using the WHO classification system","volume":"53","author":"Verghese","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2025.11.002_bib394","doi-asserted-by":"crossref","first-page":"471","DOI":"10.14694\/EdBook_AM.2012.32.23","article-title":"The creation of the international thymic malignancies interest group as a model for rare diseases","author":"Detterbeck","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtho.2025.11.002_bib395","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JTO.0000000000000154","article-title":"ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting","volume":"9","author":"Marx","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.002_bib396","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3390\/cancers14092299","article-title":"CD117, BAP1, MTAP, and TdT is a useful immunohistochemical panel to distinguish thymoma from thymic carcinoma","volume":"14","author":"Angirekula","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2025.11.002_bib397","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107479","article-title":"International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. Proposals for improvement. A RYTHMIC\/ITMIG study","volume":"189","author":"Molina","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.11.002_bib398","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2023.09.002","article-title":"The International Association for the Study of Lung Cancer thymic epithelial tumors staging project: proposal for a stage classification for the forthcoming (ninth) edition of the TNM classification of malignant tumors","volume":"18","author":"Ruffini","year":"2023","journal-title":"J Thorac Oncol"}],"updated-by":[{"DOI":"10.1016\/j.jtho.2026.103576","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000}},{"DOI":"10.1016\/j.jtho.2026.103576","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000}}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425028953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425028953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:35:39Z","timestamp":1779953739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425028953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":395,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1556086425028953"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.11.002","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}